Social facilitation maintenance treatment for adults with obesity: study protocol for a randomised-controlled feasibility study (SFM study)

Anja Hilbert

ABSTRACT
Introduction: The long-term success of non-surgical weight loss treatment in adults with obesity is limited by substantial relapse, and only a few evidence-based weight loss maintenance treatments exist. This clinical trial investigates the feasibility and efficacy of a social facilitation maintenance programme for weight loss maintenance, tailored to meet the needs of obese adults who have undergone a lifestyle weight loss intervention.

Methods and analysis: In a single-centre, open feasibility trial, 72 adults currently or previously obese or overweight who have undergone a lifestyle weight loss intervention are centrally randomised to 4 months of social facilitation maintenance treatment or treatment as a usual control condition. In 16 outpatient group sessions, the social facilitation maintenance treatment, based on a socioecological model and on evidence supporting social facilitation as a key process in maintaining weight loss, focuses on promoting interpersonal relationships to build up a healthy lifestyle for long-term weight loss maintenance.

Primary outcome is the amount of weight regain at 6-month follow-up, compared with pre-treatment weight, derived from measured body weight. Secondary outcomes address feasibility, including recruitment, attrition, assessment non-completion, compliance and patients’ programme evaluation; and in comparison with pre-weight loss maintenance, social and interpersonal functioning, eating behaviour and physical activity, psychological and physical symptoms, body composition and risk of comorbidity, and quality of life at post-treatment and follow-up assessments.

Ethics and dissemination: The study was approved by the Ethical Committee at the University of Leipzig (165-13-15072013). The study results will be disseminated through peer-reviewed publications.

Trial registration number: DRKS00005182.

BACKGROUND
Prevalence rates for obesity and overweight in adults have increased over the prior decades. Obesity is a leading cause of mortality and health-related disorders, such as type 2 diabetes mellitus and coronary heart disease. The majority of comorbidities are alleviated by modest weight loss (WL).

However, it is not the attained body mass index (BMI, kg/m²) itself, but the successful long-term maintenance of the reduced weight that is most important for the reduction of obesity-related health risks. Meta-analyses, however, suggest that in the long run, the majority of adult patients in WL programmes regain most of the weight initially lost.

This turns WL maintenance (WLM) into a major challenge in obesity management.

Reviews on the efficacy of WLM programmes provide evidence of the efficacy of behavioural interventions, although a delayed weight regain may occur. Predictor analyses indicate that psychosocial problems that often co-occur with obesity, including a lack of social support, social isolation, interpersonal distress, low self-esteem, low self-efficacy and decreased coping skills, represent major barriers to WLM.

Their importance for maintaining behaviour change in WLM, through fostering self-motivation, seems to exceed that for initiating behaviour change in WL. Several studies have documented psychosocial and interpersonal...
difficulties encountered by obese individuals, especially in clinical settings. Obese individuals face stigma and negative social interactions with strangers, acquaintances and friends in multiple domains of life, which may lead to social isolation and withdrawal. Furthermore, social impairments are frequent (eg, low socioeconomic status, poor neighbourhoods). These disadvantages are distressing and may be relevant from a psychopathological perspective, likely impairing weight management. In contrast, an extended focus on weight maintenance skills is central for effective WLM. Healthy eating behaviours (eg, regular meal patterns), self-monitoring, internal control of eating behaviour and sustained physical activity have shown positive effects on WLM. Therefore, improving psychosocial problems and weight maintenance skills may be beneficial for WLM.

Most WLM programmes focus on weight maintenance skills in the individual patient, while psychosocial problems and difficulties within the social network are usually not comprehensively addressed. The ecological model posits that facilitating factors and barriers of one’s behaviour reside on multiple levels—intrapersonal, interpersonal, social network and community. Social facilitation focuses on the enhancement of performance through interindividual influences such as the presence of others or modelling effects. Based on these concepts, and against the background of the efficacy of interpersonal psychotherapy for stabilising body weight in eating and overweight disorders, a social facilitation maintenance (SFM) programme for WLM was developed for children using empirically supported techniques to facilitate social networks that support healthy eating and physical activity. The SFM approach also targets interpersonal and intrapersonal factors identified as barriers to a healthy lifestyle. In a randomised-controlled comparison of an SFM programme, a ‘traditional’ behavioural management and a no-treatment control group, children aged 7–12 years in both active treatments maintained their relative weight better than children in the control group with medium-to-large effect sizes. During the 2 years of follow-up, both active maintenance treatments’ efficacy relative to the no-treatment control group declined, but the effects of SFM alone were significantly better than those of the no-treatment control group (d=0.45). There was indication that social problems moderated the relative weight change from baseline to 2 years of follow-up, with low social problem children in SFM versus the control group having the best outcomes. Although these results are promising and a family-based follow-up trial and an employee wellness application are underway, SFM has not yet been adapted and evaluated for WLM in adults.

Since the medical comorbidities of obesity increase healthcare costs, WLM treatment with a focus on psychosocial problems has the potential to reduce these costs. It is thus a clinical and research priority to evaluate WLM treatments such as SFM treatment. In this context, the aim of this study is to evaluate the feasibility and efficacy of SFM treatment for WLM in adults, relative to treatment as usual (TAU), in an exploratory, single-centre randomised trial. Additional objectives are to identify changes in: social and interpersonal functioning; eating behaviour and physical activity; psychological and physical symptoms; body composition and risk of comorbidity; and quality of life. Pre-treatment and sociodemographic variables, compliance, and patient motivation and expectation will be considered as outcome predictors. TAU was selected as the control condition for this first evaluation of feasibility and efficacy of an evidence-based child-focused programme in an adult-adapted version.

METHODS AND ANALYSIS

Hypotheses
1. Patients receiving SFM treatment will sustain larger amounts of WL compared with patients receiving TAU at 6-month follow-up.
2. SFM treatment in adults will be feasible.
3. Patients receiving SFM treatment will sustain larger amounts of WL at post-treatment and at 12-month and 24-month follow-up and will show greater improvements in health at post-treatment and follow-up assessments.

Design, participants and procedures

Study design
SFM treatment for adults is an exploratory, single-centre, open (ie, not blinded), prospective randomised trial, evaluating the feasibility and efficacy of SFM treatment (experimental condition) compared with TAU (control condition). The study design is depicted in figure 1. The study period lasts 4 months per patient in both conditions (4 months of SFM treatment and TAU, respectively). Following a lifestyle WL intervention, patients undergo a pre-treatment assessment (t0). Following SFM or TAU as WLM treatment over 4 months, a post-treatment assessment (t1), followed by 6-month (t2), 12-month (t3) and 24-month (t4) follow-up assessments.

Participants
A total of 72 adult patients within the lifestyle WL intervention are randomised to either SFM treatment or TAU. Inclusion criteria are summarised in box 1. To ensure generalisation of study results, exclusion criteria are kept to a minimum.

Recruitment
The ongoing study is conducted from September 2013 to June 2017 at the outpatient unit of the Integrated Research and Treatment Center (IFB) Adiposity Diseases at University of Leipzig Medical Center, Leipzig, Germany. All patients presenting at the IFB outpatient unit for lifestyle WL intervention and having consented to be contacted for participation in research studies are informed about the study and, if interested, screened for eligibility by telephone (+2). They are offered—with a
50% chance—intensive WLM treatment at no cost, and financial incentives for participation in 12-month and 24-month follow-up assessments (t3, t4 à €15). The lifestyle WL treatment at the IFB outpatient unit requires BMI $\geq 35.0$ kg/m$^2$ for admission. The WL treatment is provided under medical supervision, focuses on diet and nutrition, and includes one consultation with a physician; three 60 min individual and six 90 min nutritional counselling sessions with a nutritionist in groups of 6–10 patients; and 60 min weekly or semiweekly group-based exercise sessions for strength and/or endurance training.

Procedures
During telephone screening (t2), eligible patients are invited to a preparatory session (t1). At this session, inclusion and exclusion criteria are evaluated, written informed consent is obtained, and patients are enrolled and centrally randomised into the SFM or TAU arm by trained study staff. After finishing the lifestyle WL intervention, a pre-treatment assessment (t0) is conducted during which sociodemographic, anamnestic, anthropometric and clinical data are obtained using self-report questionnaires and objective measurement. Both SFM treatment and TAU are conducted over a 4-month period.

Ancillary study
An ancillary study investigates changes in proinflammatory cytokines, serotonin transporter availability and sleep ratings as predictors of weight change over SFM treatment (principal investigator: Hubertus Himmerich, MD). This study involves a separate consent procedure for voluntary participation offered to all patients at the preparatory session, and blood sampling and sleep-related self-report questionnaires at pre-treatment (t0) and post-treatment (t1).

**Box 1 Inclusion and exclusion criteria**

| Inclusion |
|-----------|
| Age $\geq$ 18 years; |
| $25.0$ kg/m$^2$ $\leq$ body mass index $\leq 45.0$ kg/m$^2$; |
| Previous lifestyle weight loss intervention at the Integrated Research and Treatment Center Adiposity/Diseases (IFB) outpatient unit with $\geq 50\%$ attendance; |
| Sufficient German language skills. |

| Exclusion |
|-----------|
| Serious unstable somatic conditions (eg, cardiovascular disease); |
| Serious mental conditions (eg, psychotic disorder, suicidality); |
| Bariatric surgery; |
| Use of weight-impacting medication (eg, antipsychotics); |
| Current psychotherapy; |
| Current pregnancy or lactation. |

For development of the SFM manual for adults, the existing evidence-supported SFM intervention manual for children by Wilfley et al$^{32}$ was used. SFM treatment is based on the socioecological model,$^{27}$ targeting intrapersonal and interpersonal factors identified as barriers to a healthy lifestyle in order to facilitate social networks that support healthy eating and physical activity.$^{32}$ For this study, the SFM manual for children was reorganised and shortened in order to fit with the group format. Content of sessions was adapted to adults and German culture, and interventions to foster group cohesion were added (eg, group-based games).
The overarching goal of SFM for adults is to promote interpersonal relationships to strengthen a healthy lifestyle (eating behaviour and physical activity) for long-term WLM. Therapeutic phases, sessions and topics are depicted in Table 1. The treatment consists of four phases with a focus on: (1) the patients themselves, (2) the patients’ significant others and (3) the community (eg, work setting, neighbourhood). The treatment is (4) concluded by a consolidation and relapse prevention phase. The first phase (sessions 1–4) guides patients to review their eating behaviour and physical activity routines for long-term WLM, and addresses changes in the physical and social home environment. The second phase (sessions 5–8) focuses on changes in the social network fostering healthful eating and physical activity. The third phase (sessions 9–11) addresses changes in the work environment and neighbourhood, with a concentration on the promotion of social physical activity. The fourth phase (sessions 12–16) focuses on coping with weight-related stigma as a barrier to healthful eating and physical activity, on the consolidation of therapeutic gains and on the management of anticipated relapse.

Across these phases, interpersonal problems (eg, lack of social support, communication problems, stigma) and intrapersonal problems (eg, negative thinking, self-stigma, negative body image) are addressed.

SFM treatment is delivered in groups of 6–10 patients within 16 weekly sessions of 2 hours duration. It is provided by a psychologist with training in behaviour therapy and, specifically, SFM. Empirically supported therapeutic techniques are used (eg, psychoeducation, self-monitoring, goal setting, self-reinforcement, problem-solving, communication training). Major differences between the adult SFM manual and the child SFM manual reside in structure and content (eg, group therapy vs combined family and individual therapy; tailoring of exercises to group format; and adult-relevant topics, eg, work setting). Treatment fidelity is ensured through regular supervision, also preventing a drift in treatment delivery.

Control intervention—TAU

The TAU control condition consists of one visit with a physician, and up to five 60 min individual nutritional

| Table 1 Therapeutic phases, sessions and topics |
|-----------------------------------------------|
| **Phase**                                    |
| Focus on self                                |
| Focus on significant others                   |
| Focus on community                           |
| Focus on consolidation and relapse prevention |
| **Sessions**                                 |
| (1) Introduction                             |
| (2) Healthy behaviours                        |
| (3) Healthy home environment                  |
| (4) Self-reinforcement                        |
| (5) Social network support                    |
| (6) Changing the social network              |
| (7) Healthy meetings                          |
| (8) Communication                             |
| (9) Work environment                          |
| (10) Neighbourhood                            |
| (11) Physical activity with others            |
| (12) Stigma                                   |
| (13) Stigma and body image                   |
| (14) Motivation and relapse prevention        |
| (15) Consolidation                            |
| (16) Certification                            |
| **Topics**                                   |
| Introduction                                  |
| Socioecological model                         |
| Meal routines                                 |
| Physical activity and sleep routines          |
| Barriers and resources at home                |
| Social support at home                        |
| Communication training                        |
| Barriers and resources in the social network  |
| Planning and initiation of change regarding healthy eating and physical activity |
| Arrange meetings in a healthy way regarding eating and physical activity |
| Initiating and maintaining friendships         |
| Communication training                        |
| Barriers and resources at work                |
| Planning and initiation of change             |
| Barriers and resources in the neighbourhood   |
| Planning and initiation of change             |
| Relevance of physical activity with others    |
| Planning and initiation of change             |
| Weight-related stigma (eg, critical comments) and consequences for healthy lifestyle |
| Social competence training                    |
| Media messages and stigma                     |
| Self-stigma and body image                   |
| Relevance of motivation                       |
| Lapse and relapse                             |
| Coping with relapse                           |
| Repetition of central behaviours for long-term WLM |
| Farewell                                      |
| Conferment of certificates                    |

WLM, weight loss maintenance.

The BMJ logo is a registered trademark of the British Medical Journal Limited. The BMJ logo is used under license from BMJ Limited. Redistribution or republication of the majority of BMJ content is prohibited without the prior written permission of BMJ Limited.
counselling sessions with a nutritionist over 4 months, in addition to 60 min weekly or semiweekly physical activity sessions as described. This TAU is the commonly offered treatment at the IFB outpatient unit.

Measures
Primary and secondary outcomes
The primary outcome measure is the weight regain (kg) at 6-month follow-up (t2, 10 months after t0), compared with pre-treatment weight (t0), both derived from objectively measured body weight through calibrated instruments. Weight regain is consistently reported as the primary outcome measure in WLM trials. The secondary outcome of measurement of weight at post-treatment (t1, 4 months after t0) will provide insight into the change of the primary outcome over WLM treatment. Self-report of weight at 12-month follow-up (t3, 16 months after t0) and at 24-month follow-up (t4, 28 months after t0) will provide evidence of the long-term maintenance of effects.

Feasibility of the study procedures in general and of delivering SFM to adults are evaluated by assessing recruitment, attrition, assessment completion, compliance and patients’ programme evaluation as secondary outcome measures when appropriate (between pre-treatment and post-treatment). Further secondary outcomes include measures of: social and interpersonal functioning; eating behaviour; physical activity; psychological and physical symptoms; and quality of life. The assessments are conducted at pre-treatment (t0); at post-treatment (t1); and at 6-month, 12-month and 24-month follow-ups (t2, t3, t4). BMI (kg/m²) is calculated from measured (t0, t1, t2) or self-reported (t3, t4) weight and height. Further indicators of body fatness and/or composition and cardiovascular risk are determined (waist circumference, blood pressure, skinfolds, bioelectrical impedance analysis; t0, t1, t2).

We chose these outcome measures because they exhibit good psychometric properties, are well established in German and are used in international research studies. The raters have no therapeutic relationship with the patients. They underwent extensive training for conducting the assessments and receive ongoing supervision for standardised administration (drift prevention).

Predictor variables
Predictor variables, assessed at pre-treatment (t0) and post-treatment (t1), consist of all outcome variables, sociodemographic variables, compliance, and patient motivation and expectation ratings assessed through visual analogue scales.

Methodological aspects
Power analysis
Owing to the preliminary nature of this feasibility trial, estimation of sample size based on a power analysis was not deemed necessary. An analysis set consisting of 60 patients (30 patients per study arm) is expected to provide estimates for changes in weight with a 95% CI of 5 kg. Such precision is more than adequate for a subsequent confirmatory trial. This sample calculation is based on a meta-analysis of extended WLM care versus no intervention for which a Hedges g of 0.385 is expected. The t-test would then provide a power of 55%. Assuming a dropout rate of 20% of patients over the course of the study, 72 patients are recruited for the study. This rate is based on dropout rates of 4–24% of previous WLM treatment studies. For patients who discontinue or deviate from the intervention protocol, it is nevertheless planned to conduct assessments and complete follow-ups. Efforts to retain as many participants as possible throughout the study period include information on the relevance and necessity of the study, use of continuity forms locating participants throughout the study period, and use of incentives for follow-up assessments.

Randomisation
Patients meeting study criteria are enrolled and randomised by trained study staff after giving written informed consent. To ensure concealment of allocation, the randomisation is centrally performed using an online randomisation tool hosted by the Coordination Center for Clinical Trials of the University of Leipzig. Randomisation is based on Pocock’s minimisation algorithm and stratified by sex. The allocation ratio between the two study arms is 1:1.

Blinding
Assessments are performed by independent raters who have no therapeutic relationship with the patients. Blinding of treatment to raters and patients is not possible because of the small scope of this study, and because patients know the study arm from the particular modes of delivery.

Data analytic plan
The primary outcome of ‘weight regain at 6-month follow-up (t2)’ will be investigated by calculating an effect size with a 95% CI for each arm separately. In addition, a mixed model will be used with weight at 6-month follow-up (t2) as the dependent variable, and weight at pre-treatment (t0) and study arm as fixed effects, with the group within study arm as a random effect. This confirmatory analysis follows the intent-to-treat principle and will be based on the full analysis set. Every attempt is made to acquire missing data. If data missing for the primary outcome can be expected to bias results in a meaningful way, multiple imputation will be performed. Further, the analysis of the primary outcome will be performed in the per-protocol set to evaluate the treatment effect for patients with good protocol adherence. The primary outcome will be further analysed in an exploratory manner as in the primary analysis, but will also include sex and intervention group.
Secondary outcomes will be analysed in an exploratory, descriptive manner, and will be evaluated by means of effect sizes, presented with 95% CIs, as well as parametric or non-parametric tests, depending on the scale level and type of distribution of the observed variables. Maintenance of treatment success over time will be evaluated. Predictors of treatment outcome will be identified using regression analyses.

Monitoring and data management
The trial is performed in cooperation with the Coordination Center for Clinical Trials of the University of Leipzig, which is responsible for monitoring and data management. After data entry, data are monitored for completeness, consistency and plausibility. Errors in data entry are determined in a stepwise procedure, examining all data of five patients and, depending on error rates, examining all data in up to an additional 25% of the patients. Data quality is ensured through plausibility checks (eg, examination of ranges). During and after trial implementation, data will be collected and stored on servers of the Coordination Center for Clinical Trials, and thus behind the firewall of the University of Leipzig. Access to the servers is secured via https protocol, and requires user-specific login and password. Post-treatment data will be released only after study completion (ie, after termination of the 24-month follow-up). No interim analyses are planned. AH will be granted access to the final trial data set. The study data will be reported in accordance with the extended CONSORT guidelines for non-pharmacological treatment studies.56

Confidentiality
All clinical data recorded by the trial personnel at the trial site on paper case report forms will be entered into the database at the Coordination Center for Clinical Trials Leipzig by using a trial identification number that does not reference the patient’s personal identifiers (pseudonymised data). In the event of withdrawal of consent, the necessity for storing data will be evaluated. Data that are not needed will be deleted as requested, with full documentation of the reasons for deletion. Data analysis will be performed solely using de-identified data. After trial publication, trial data will be shared in de-identified form on request.

Personal information about potential and enrolled participants collected during enrolment will only be stored at the trial site and be subject to the raters’ and therapists’ privacy obligation. Personal information will not be shared and will be deleted after the trial.

Ethics and dissemination
Ethical approval
The study was approved by the Ethical Committee of the Medical Faculty at University of Leipzig (165-13-15072013). Written informed consent is obtained by trained staff after the study has been fully explained and prior to randomisation (a model consent form is available on request). Patients can withdraw at any time without any disadvantage. The trial is conducted in accordance to the guidelines for good clinical practice (GCP).57 All persons participating in the conduct of the trial commit themselves to the Declaration of Helsinki (Version Somerset West 1996),58 as well as all pertinent national laws and the ICH guidelines for GCP and CPMP/ICH/135/95.59 All protocol modifications including changes to eligibility criteria, outcomes or analyses are reported to the Ethical Committee.

Safety
Adverse events are all unwanted medical events (eg, emerging or aggravating symptoms) occurring throughout the trial, whether or not they have a causal association with the trial. Adverse events are documented at every assessment and at every week of treatment throughout the trial. They are rated according to severity: serious adverse events are those that led to death, are life-threatening, make inpatient treatment necessary, lead to sustained harm, or cause birth defects or deformities. Serious adverse events include mental or physical decompensations that indicate a need for hospitalisation (eg, acute suicidality). Adverse events are recorded through a self-report assessment of somatic symptoms45 46 at pre-treatment (t0) through 6-month follow-up (t2) and an unstandardised reporting of adverse events every week during treatment. Any serious adverse event is immediately reported to the Ethical Committee of the University of Leipzig. In case of adverse events making ancillary or post-trial care necessary, participants are referred to local medical care services.

Owing to the small scope of this exploratory study and non-psychotherapeutic intervention, an independent Data Monitoring and Safety Committee was not deemed to be necessary.

Dissemination
The study results will be disseminated through peer-reviewed publications and conference presentations to the scientific community, and through further presentations to the public and healthcare professionals. No restrictions on publication exist. Authorship will follow the rules of good scientific practice of the German Research Foundation, and no professional writers will be used.

Acknowledgements
The author is grateful to Nicole Koepp-Baurnfeind and Petra Neuhaus for their input on the study protocol, preparation of case report forms, management of ethical requirements, and organisation of randomisation and data management; to David Petroff for his input on data analytic design; to Denise E Wilfley for providing the social facilitation maintenance (SFM) manual for children, granting the permission for and supporting the adaptation of the SFM manual to adults; to Claudia Hübner for her input on the study protocol, SFM manual for adults, and organisation of the study; to her and to Lisa Schäfer for their contribution to the conduct of this study; and to all mentioned persons from University of Leipzig for their input on this paper. The author is further grateful to Lisa Opitz and Jamie L Manwaring for their editing of this paper.
Funding This work was supported by grant 01EO1001 from the German Federal Ministry of Education and Research.

Competing interests None declared.

Ethics approval Ethical Committee at the University of Leipzig.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement The manuscript reports on a study protocol for a clinical trial. After trial publication, trial data will be shared in de-identified form on request.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

REFERENCES

1. Ong M, Fleming T, Robinson M, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2014;384:766–81.

2. Mensink GB, Schienkiewitz A, Haftenberger M, et al. [Overweight and obesity in Germany 2019: results of the German Health Interview and Examination Survey for Adults (DEGS1)]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2015;58:766–94.

3. Fiegel KM, Kit BK, Orpina H, et al. Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. JAMA 2013;309:71–82.

4. Schienkiewitz A, Mensink GB, Scheidt-Nave C. Comorbidity of overweight and obesity in a nationally representative sample of German adults aged 18–79 years. BMC Public Health 2012;12:658.

5. Wing RR, Bolin MC, Scanlan RL, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 2013;369:145–54.

6. Diabetes Prevention Program Research Group. Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study. Lancet Diabetes Endocrinol 2015;3:866–75.

7. Rueda-Clausen CF, Ogunele AA, Sharma AM. Health benefits of long-term weight-loss maintenance. Ann Nutr Metab 2015;5:475–516.

8. Dixon JB, Anderson M, Cameron-Smith D, et al. Sustained weight loss in obese subjects has benefits that are independent of attained weight. Obes Res 2004;12:1895–902.

9. Dombrowski SU, Knittle K, Avenell A, et al. The impact of personality traits on the success of a multimodal obesity treatment. Behav Med 2008;34:191–98.

10. Reiger E, Treasure J, Swinbourne J, et al. The effectiveness of including support people in a cognitive behavioural weight loss maintenance programme for obese adults: study rationale and design. Clin Obes 2014;4:77–90.

11. Lo Coco G, Guollo S, Scrima F, et al. Obesity and interpersonal problems: an analysis with the interpersonal circumplex. Clin Psychol Psychother 2012;19:390–8.

12. Puhl R, Brownell KD. Bias, discrimination and obesity. Obes Res 2001;9:789–905.

13. Puhl RM, Moss-Racusin CA, Schwartz MB, et al. Weight stigmatization and bias reduction: perspectives of overweight and obese adults. Health Educ Res 2008;23:347–58.

14. Puhl RM, Heuer CA. The stigma of obesity: a review and update. Obesity (Silver Spring) 2006;14:1741–47.

15. Wardle J, Chida Y, Gibson EL, et al. Stress and adiposity: a meta-analysis of longitudinal studies. Obesity (Silver Spring) 2011;19:771–84.

16. Goldschmidt AB, Best JR, Stein RI, et al. Predictors of child weight loss and maintenance among family-based treatment completers. J Consult Clin Psychol 2014;82:1140–50.

17. Teixeira PJ, Carraça EV, Marques MM, et al. Successful behavior change in a multi century intervention: a systematic review of self-regulation mediators. BMC Med 2015;13:84.
46. Kroenke K, Spitzer RL, Williams JB. The PHQ-15: validity of a new measure for evaluating the severity of somatic symptoms. *Psychosom Med* 2002;64:258–66.

47. Hilbert A, Baldofski S, Zenger M, et al. Weight Bias Internalization Scale: psychometric properties and population norms. *PLoS ONE* 2014;9:e86303.

48. Schwarzer R. *Streß, Angst und Handlungsregulation*. 4th edn. Stuttgart: Kohlhammer, 2000.

49. Lillis J, Luoma JB, Levin ME, et al. Measuring weight self-stigma: the Weight Self-stigma Questionnaire. *Obesity* 2010;18:971–6.

50. Kolotkin RL, Crosby RD, Kosloski KD, et al. Development of a brief measure to assess quality of life in obesity. *Obes Res* 2001;9:102–11.

51. Middleton KM, Patidar SM, Perri MG. The impact of extended care on the long-term maintenance of weight loss: a systematic review and meta-analysis. *Obes Rev* 2012;13:509–17.

52. Rieber N, Hilbert A, Teufel M, et al. Gewichtsstabilisierung nach Gewichtsreduktion. *Adipositas* 2010;4:115–24.

53. Wantland DJ, Portillo CJ, Holzemer WL, et al. The effectiveness of web-based vs. non-web-based interventions: a meta-analysis of behavioral change outcomes. *J Med Internet Res* 2004;6:e40.

54. Mitchell JE, Crosby RD, Wonderlich SA, et al. A randomized trial comparing the efficacy of cognitive-behavioral therapy for bulimia nervosa delivered via telemedicine versus face-to-face. *Behav Res Ther* 2008;46:581–92.

55. Pocock SJ. Current issues in the design and interpretation of clinical trials. *BMJ* 1985;290:39–42.

56. Boutron I, Moher D, Altman DG, et al. Extending the CONSORT statement to randomized trials of nonpharmacologic treatment: explanation and elaboration. *Ann Intern Med* 2008;148:295–309.

57. Bundesministerium der Justiz. Verordnung über die Anwendung der Guten Klinischen Praxis bei der Durchführung von klinischen Prüfungen mit Arzneimitteln zur Anwendung am Menschen (GCP-Verordnung—GCP-V). Bonn: BGBl. I 3394, 2012. http://www.gesetze-im-internet.de/bundesrecht/gcp-v/gesamt.pdf (accessed 02 Sep 2015).

58. World Medical Association. Declaration of Helsinki: guiding physicians in biomedical research involving human subjects. Helsinki, 2013. http://www.wma.net/en/30publications/10policies/b3/ (accessed 02 Sep 2015).

59. International Conference on Harmonisation of technical requirements for the registration of pharmaceutical products for human use. *ICH Harmonized Tripartite Guideline*, "Guideline for Good Clinical Practice"; 1996. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R1_Guideline.pdf (accessed 2 Sep 2015).